Desonide
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Desonide: From Inflammatory Skin and Allergic Conditions to Polyp of Vocal Cord
One-Sentence Summary
Desonide is a low-potency topical corticosteroid, originally used for inflammatory and allergic conditions such as atopic and seborrheic dermatitis. The TxGNN model predicts it may be effective for polyp of vocal cord, but no clinical trials and no publications currently support this prediction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not stated in the Singapore licence records. The knowledge graph lists inflammatory skin conditions (e.g. atopic dermatitis, contact dermatitis, seborrheic dermatitis) and several allergic or inflammatory conditions (e.g. asthma, allergic rhinitis, inflammatory bowel disease) |
| Predicted New Indication | Polyp of vocal cord |
| TxGNN Prediction Score | 99.91% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 2 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available. Based on known information, desonide is a low-potency topical glucocorticoid with anti-inflammatory activity. Its efficacy in inflammatory skin disease is established, and mechanistically an anti-inflammatory effect could reduce swelling in inflammatory lesions.
The link to vocal cord polyps is weak, however. These lesions are mainly mechanical or related to voice trauma, and are typically managed by voice therapy or surgery. A topical dermatologic cream or lotion has no established route of delivery to the larynx. The prediction therefore rests only on the model score.
The other top predictions follow the same pattern, and all share the same limitations:
| Rank | Predicted Indication | Score | Evidence Level | Comment |
|---|---|---|---|---|
| 2 | Polyp of middle ear | 99.91% | L5 | Corticosteroids are used in ear inflammation, but treatment is surgical or targets the underlying disease |
| 3 | Polyp of external auditory canal | 99.91% | L5 | Skin-lined canal makes topical delivery plausible, but no evidence for effect on polyp tissue |
| 4 | Polyp of frontal sinus | 99.91% | L5 | Class-level rationale from sinonasal polyposis, but desonide is not designed for sinus delivery |
| 5 | Polyp of ureter | 99.90% | L5 | No plausible mechanism or delivery route |
| 6 | Polyp of vulva | 99.90% | L5 | Topical delivery feasible, but these lesions are treated by excision |
| 7 | Fibroepithelial polyp | 99.90% | L5 | Benign overgrowth treated by excision |
| 8 | Neoplastic polyp | 99.90% | L5 | No known antineoplastic action; speculative |
| 9 | Epulis | 99.90% | L5 | Product not formulated for oral mucosa |
| 10 | Uterine polyp | 99.90% | L5 | No delivery route or known mechanism |
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN08252P | DESOWEN CREAM 0.05% | Cream | Not stated in the data compiled |
| SIN08572P | DESOWEN LOTION 0.05% | Lotion | Not stated in the data compiled |
Both licences are valid single-ingredient products from Laboratoires Galderma. The available formulations are topical (cream and lotion).
Safety Considerations
- Knowledge-graph contraindication signals (from drug-disease associations, not label text): hypertension, congestive heart failure, epilepsy, liver disease, gallbladder disease, hyperglycaemia, measles, herpes simplex virus keratitis, urea cycle disorders (carbamoyl phosphate synthetase I deficiency, hyperargininemia, citrullinemia), and pituitary or growth hormone deficiency disorders (including hypopituitarism, hypogonadotropic hypogonadism and Kallmann syndrome). Many of these reflect systemic corticosteroid class effects and may be less relevant for low-potency topical use. They should be verified against the package insert.
- Drug Interactions: No interaction records were found.
Please refer to the package insert for further safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is supported only by the model score, with no clinical trials or literature. There is also no plausible delivery route from a topical dermatologic product to the larynx. The same applies to the other top-ranked polyp predictions.
To proceed, the following is needed:
- Package insert warnings and contraindications from the HSA, which are required before safety screening
- Detailed mechanism of action data (MOA)
- Route-of-administration compatibility assessment for the target site, and a clear rationale for why a corticosteroid would act on polyp tissue
- Any preclinical or clinical studies of desonide or related corticosteroids in polypoid lesions, to move beyond L5
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.